Paper Details

  1. Home
  2. Paper Details

Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.

Author: AbbasAlexander, ArnoldDirk, DucreuxMichel, GilbergFrank, GrotheyAxel, IraharaNatsumi, O'DwyerPeter J, PrizantHen, SchmollHans-Joachim, TaberneroJosep, TahiriAnila, ThakurMeghna Das, Van CutsemEric, de GramontAimery

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

MODUL is an adaptable, signal-seeking trial of biomarker-driven maintenance therapy following first-line induction treatment in patients with metastatic colorectal cancer (mCRC). This report describes findings from Cohorts 1 (BRAFmut), 3 (HER2+) and 4 (HER2−/high microsatellite instability, HER2−/microsatellite stable [MSS]/BRAFwt or HER2−/MSS/BRAFmut/RASmut).
Paper Details　
Original Abstract of the Article :
Label="PURPOSE">MODUL is an adaptable, signal-seeking trial of biomarker-driven maintenance therapy following first-line induction treatment in patients with metastatic colorectal cancer (mCRC). We report findings from Cohorts 1 (BRAF<sup>mut</sup>), 3 (human epidermal growth factor 2 [HER2]+) and 4...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejca.2023.01.023

データ提供：米国国立医学図書館（NLM）

Personalized Therapy: The Future of Metastatic Colorectal Cancer Treatment?

Oncology is a rapidly evolving field, and this study explores the potential of biomarker-driven maintenance therapy for metastatic colorectal cancer (mCRC). The authors report on the findings from the MODUL trial, an adaptable, signal-seeking trial that investigates the effectiveness of personalized treatment approaches based on specific biomarkers.

Unlocking the Secrets of Personalized Treatment

The study found that the biomarker-driven approach to treatment showed promising results for different patient subgroups, suggesting that personalized therapy could be a valuable tool for managing mCRC. The study found that patients with BRAF mutations, HER2-positive tumors, and HER2-negative/high microsatellite instability tumors responded differently to treatment, highlighting the importance of tailoring therapy to individual patient profiles. Think of it as a map through the desert - the same path may not lead to the same destination for everyone.

Hope for a Brighter Future

This study offers a glimpse into the future of mCRC treatment. It demonstrates the potential of personalized therapy to improve patient outcomes and offers hope for a more effective approach to managing this complex disease. It's a reminder that the desert of cancer treatment is vast and challenging, but by understanding individual patient needs and utilizing innovative therapies, we can pave the way for a brighter future.

Dr. Camel's Conclusion

This study is a testament to the power of personalized medicine in oncology. By utilizing biomarkers to tailor treatment approaches, we can potentially achieve better outcomes for patients with mCRC. It's a reminder that the journey through the desert of cancer treatment is not a one-size-fits-all approach, and that finding the right path requires a deep understanding of individual needs and the latest advancements in medical science.

Date :
  1. Date Completed 2023-04-17
  2. Date Revised 2023-04-17
Further Info :

Pubmed ID

36921494

DOI: Digital Object Identifier

10.1016/j.ejca.2023.01.023

Related Literature

Article Analysis
・Effects of cobimetinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.